Membranous Nephropathy： Muti-omics Mendelian randomization and colocalization analysis

Zhihang Su[1], Wen Liu[1], Zheng Yin[1], Di Wu[1], Yuan Cheng[1], Qijun Wan[1]*

[1]Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of
Shenzhen University, Shenzhen, China

* Correspondence:
Qijun Wan (Email: yiyuan2224@sina.com)

Word Count:

Abstract: 388 words

Text (excluding references):   3364 words

Keywords: Membranous nephropathy, Mendelian randomization, Plasma Protein, Therapeutic
targets, genome-wide association study (GWAS), Colocalization, expression quantitative trait
Loci (eQTL), Protein quantitative trait loci (pQTL).

Abstract

Background:

The currently available medications for treating membranous nephropathy (MN) still have
unsatisfactory efficacy in inhibiting disease recurrence, slowing down its progression, and even
halting the development of end-stage renal disease. There is still a need to develop novel drugs
targeting MN.

Methods:

We utilized summary statistics of MN from the Kiryluk Lab and obtained plasma proteins from
Zheng et al., Decode, and UKBioBank and gene data from eQTLgen and GTEX. We performed a
two-sample Bidirectional mediation Mendelian randomization analysis, SMR analysis, HEIDI test,
Bayesian colocalization, phenotype scanning, external validation, mediation analysis, drug bank
analysis, and protein-protein interaction network.

Results:

The Mendelian randomization analysis uncovered 8 distinct proteins associated with MN after False
Discovery Rate multiple correction. Proteins associated with an increased risk of MN in plasma
include ABO [(Histo-Blood Group Abo System Transferase) (WR OR = 1.116, 95%CI：1.047-
1.190, FDR=0.090, PPH4 = 0.795)], VWF [(Von Willebrand Factor) (WR OR = 1.412, 95%CI：
1.157-1.725, FDR=0.018, PPH4 = 0.816)] and CD209 [(Cd209 Antigen) (WR OR = 1.187, 95%CI
：1.074-1.312, FDR=0.090, PPH4 = 0.795)], and proteins that have a protective effect on MN: HRG
[(Histidine-Rich Glycoprotein) (WR OR = 1.814, 95%CI：1.345-2.445, FDR=0.018, PPH4 =

0.797)], CD27 [(Cd27 Antigen) (WR OR = 0.785, 95%CI：0.681-0.904, FDR=0.018, PPH4 =
0.797)], LRPPRC [(Leucine-Rich Ppr Motif-Containing Protein, Mitochondrial) (WR OR = 0.790,
95%CI：0.688-0.907, FDR=0.090, PPH4 = 0.797)], TIMP4 [(Cd27 Antigen) (WR OR = 0.666,
95%CI：0.527-0.840, FDR=0.090PPH4 = 0.833)] and MAP2K4 [(Metalloproteinase Inhibitor 4)
(WR OR = 0.815, 95%CI：0.723-0.919, FDR=0.090, PPH4 = 0.797)]. None of these proteins
exhibited a reverse causal relationship. Bayesian colocalization analysis provided evidence that all of
them share variants with MN. In external validation, ABO, CD27, HRG, MAP2K4, TIMP4, and
VWF showed significant mediation results. We identified type 1 diabetes, trunk fat, and asthma as
having intermediate effects in these pathways. We discovered several genes that are causally related
to MN.

Conclusions:

Our comprehensive analysis indicates a causal effect of ABO, CD209, CD27, HRG, LRPPRC,
MAP2K4, and TIMP4 at the genetically determined circulating levels on the risk of MN. These
proteins have the potential to be a promising therapeutic target for the treatment of MN. We
identified type 1 diabetes, trunk fat, and asthma as having intermediate effects in these pathways. We
discovered several genes that are causally related to MN.

1   Introduction

Membranous Nephropathy (MN) is a common chronic autoimmune disease.
MN may occur in both sexes and all ethnic groups. It is widely acknowledged that MN is the most
common cause of adult nephrotic syndrome(1). The prognosis of MN is challenging to predict, as
some patients may experience spontaneous remission while others progress to end-stage renal
disease(2). Current mainstream treatments for MN include cyclophosphamide, glucocorticoids,
rituximab, and calcineurin inhibitors(3). In contrast to newly developed therapies targeting BAFF,
plasma cells, and complement(4), human circulating proteins play a crucial role in various biological
processes and serve as primary drug targets(5). The relevant literature has shown that protein drug
targets with genetic associations supporting their connection to diseases are more likely to become
drug targets and gain market recognition compared to targets discovered by chance(6,7). In recent
times, the application of Mendelian randomization (MR) analysis has gained significant traction in
identifying potential therapeutic targets and repurposing drugs(8). As an approach within genetic
instrumental variable analysis, MR employs single nucleotide polymorphisms (SNPs) as instrumental
variables (IVs) to estimate the causal relationship between exposures and outcomes(9). Compared to
traditional observational studies, MR has the ability to mitigate the impacts of type I errors and
confounding factors(10). As a result of advancements in large-scale genomic and proteomic
technologies, the utilization of MR-based strategies has enabled the discovery of promising targets
for therapeutic interventions in a variety of disorders, including Heart Failure(11), multiple
sclerosis(12), and inflammatory bowel disease(13). However, no MR study reports have integrated
GWAS of MN and protein quantitative trait loci (pQTL) data to date. In the present investigation, our
focus was to ascertain plasma as a viable candidate for therapeutic intervention in the case of MN.
Figure 1 depicts the study design. Initially, we utilized MN data from Kiryluk Lab and plasma pQTL
data to discern plausible causal plasma proteins associated with MN.(14) Next, we further validated
the initial findings using Steiger filtering, Bayesian colocalization analysis, and phenoscanner. In a
subsequent step, we constructed an interaction network linking potential protein targets with MN
drug targets. Lastly, for reinforcement of our conclusions, we also conducted external validation. We

assessed the mediating factors between these significant proteins and MN. Finally, we analyzed the
relationship between the genes of these significant proteins and MN using expression quantitative
trait Loci (eQTL) data, GTEX, the smr method, and the HEIDI test.

2   Methods

2.1   Plasma protein quantitative trait loci

We incorporated pQTLs that fulfilled the subsequent set of criteria: ① demonstrating a

significant correlation at the genome-wide level (P < 5e-8); ② being situated outside the major

histocompatibility complex (MHC) region (chr6, 26-34Mb); ③ demonstrate distinct associations
[linkage disequilibrium (LD) clustering r^2 < 0.001]. In the preliminary analysis, we extracted
plasma pQTL data from public research,(14) which consolidated findings from five public
studies(15–19). With regard to the aforementioned selection criteria, a total of 2,113 cis and trans
SNPs associated with 1,699 proteins were included. The aforementioned databases have been
concurrently utilized in previous studies, alleviating concerns regarding their reliability.(12) Each
database will be treated as an individual sample, and we will conduct MR on each of them. Plasma
pQTL data of external validation was retrieved from recent study. Decode encompassed 35,559
participants enabling the quantification of a total of 4,907 plasma proteins(20). UKB-PPP
encompassed 54,219 participants, enabling the quantification of a total of 2,923 plasma proteins(21).
The above databases are all derived from European populations.

2.2   Genome-wide association study data of Membranous nephropathy

Aggregate statistical data of MN, including individuals of European ancestry (Sample size of
Cases=2150, Sample size of Control=5829, size of SNPs=5,327,688), were retrieved from the
Kiryluk Lab.(22) All cases included in the final database were diagnosed as idiopathic membranous
nephropathy using the gold standard method of renal biopsy. Furthermore, potential causes of
secondary membranous nephropathy, such as medication, malignancies, infections, and autoimmune
diseases, were systematically ruled out. Nonetheless, the study did not present a detailed description
of the target antigens in the patients.

2.3   Mendelian randomization analysis

2.3.1 Selection of Instrumental Variables
The IVs must meet the mentioned assumptions: relevance, exogeneity, and independence.

i.   The IVs must exhibit a strong association with plasma protein. First, we selected SNPs falling
beneath the locus-wide significance cutoff (5×10^{-8}).
ii.   The clumping processes were executed to maintain the IVs' independence and remove the
linkage disequilibrium (LD) effect. Linkage disequilibrium (r²) was set at 0.001, and genetic
distance was set at 10,000 kb.
iii. F = R2(n - k - 1)/ k (1 - R2), where R2 is the exposure variance calculated based on the data
within the dataset. The number of IVs is k, and the samples are n. When F-statistic **<** 10, it
indicates weak IVs, and they will be excluded.

Within this study, proteins were investigated as the primary variable of interest, representing the
exposure, while MN served as the focal point of analysis, representing the outcome. The Wald ratio

(WR) was utilized when it came to one SNP(23). When two or more SNPs were accessible (the
numbers of SNPs≥2), we utilized the inverse variance weighted (IVW) method, followed by
assessments of heterogeneity and horizontal pleiotropy(24). In the process of conducting Mendelian
randomization (MR), in cases where effect allele frequency data is missing, we employ data from the
1000 Genomes project (HG19/GRCh37) as a substitute. The amplified risk of MN was indicated as
odds ratios (OR) per one-unit change in plasma protein levels, corresponding to a standard deviation
(SD) increase.

2.4   Reverse causality detection and sensitivity analysis

In the presence of a sufficient number of SNPs, we will conduct a bidirectional MR analysis. If an
adequate number of SNPs is not available, we will resort to Stiger filtering as an alternative, which is
also a directional testing method(25). Unlike most methods based on GWAS data, the Heterogeneity
in Dependent Instruments (HEIDI) test is used to distinguish between pleiotropy and linkage models.
Associations with a HEIDI test p-value < 0.05 are considered to be caused by pleiotropy and are
therefore removed from further analysis. The SMR software tool (SMR v1.0.3) was used for SMR
analysis.

2.5   Bayesian colocalization analysis

Colocalization analysis was employed to evaluate the likelihood of two traits sharing a common
causal variant. As previously mentioned, the posterior probabilities of five hypotheses were utilized
to provide detailed supplementation to the results of colocalization analysis. Specifically, the first
hypothesis (PPH0) indicates "No association with either trait." The second hypothesis, posterior
probabilities of hypotheses (PPH1), represents, in this gene segment, there is only an association with
trait 1 but not with trait 2. Lastly, the third hypothesis (PPH2) signifies "Association with trait 2, but
not with trait 1." In our research, we assessed the posterior probabilities of hypotheses 3 and 4
(PPH3, PPH4).(26) In hypothesis 3, exposure (plasma protein) and outcome (MN) are linked to the
genomic region through different SNPs, while in hypothesis 4, the protein and MN are both linked to
the genomic region through a shared SNP. By employing the coloc.abf algorithm, we defined genes
as having gene-based colocalization evidence when PPH4 > 80%.

2.6   Phenoscanner

144   We also employed Phenoscanner to uncover the connections of identified pQTLs with other
145   traits. SNPs were classified as having horizontal pleiotropy when they exhibited connections with
146   established risk factors for MN, encompassing metabolic traits, proteins, or clinical characteristics.

2.7   Mediation analysis

We conducted a mediation analysis on significant proteins using a two-step Mendelian randomization
approach to identify the mediating factors. The overall influence of exposure on the outcomes was
categorized into direct effects and indirect effect(27). Specifically, the total effects of the identified
plasma proteins on MN in this study encompassed two components: 1) the direct effects of the
identified plasma proteins on MN, calculated through primary MR analysis; and 2) using the product
method to estimate the indirect effects mediated by the identified risk factors. Standard errors (SE)
and confidence intervals (CI) were determined employing the delta method.

2.8   SMR analysis

156 We further performed SMR analysis to identify genes that may have a causal relationship with MN.
157 The data used for analysis were sourced from eqtlgen and GTEX (28). The HEIDI test was
158 concurrently utilized to distinguish between pleiotropy and linkage models.

2.9   Protein-protein interaction network

In the plasma analysis, we investigated proteins potentially associated with MN. We primarily
employed MR analysis with a significance level of FDR < 0.10 and directional tests. Furthermore, we
explored the target proteins of drugs for MN available in the market. We identified these targeted
drugs through a comprehensive review of the literature and by searching the DrugBank database
(DrugBank | Powering health insights with structured drug data).(29,30) Additionally, we conducted
a search for drugs targeting the potential pathogenic proteins we identified. Subsequently, protein-
protein interaction (PPI) networks were employed to investigate the interplay among the proteins and
the relevant targets. All PPI analyses were executed utilizing version 12.0 of the STRING database
[STRING: functional protein association networks (string-db.org)],(31) with a predefined minimum
threshold set at 0.5.

3   Results

3.1   Mendelian randomization analysis

Following the adherence to the principles of instrumental variable selection, a comprehensive set of
1057 IVs were included in the analysis. After False Discovery Rate multiple correction, employing a
nominal significance threshold (P < 0.10), the MR analysis s identified 8 protein-MN associations.
We discovered plasma proteins associated with an increased risk of MN: ABO [(Histo-Blood Group
Abo System Transferase) (WR OR = 1.12, 95%CI：1.05-1.19, FDR=0.09, PPH4 = 0.80)], VWF
[(Von Willebrand Factor) (WR OR = 1.412, 95%CI：1.16-1.73, FDR=0.02, PPH4 = 0.82)] and

CD209 [(Cd209 Antigen) (WR OR = 1.19, 95%CI：1.07-1.31, FDR=0.09, PPH4 = 0.80)] and
proteins that have a protective effect on MN: HRG [(Histidine-Rich Glycoprotein) (WR OR = 1.81,
95%CI：1.35-2.45, FDR=0.02, PPH4 = 0.80)], CD27 [(Cd27 Antigen) (WR OR = 0.79, 95%CI：
0.68-0.90, FDR=0.02, PPH4 = 0.80)], LRPPRC [(Leucine-Rich Ppr Motif-Containing Protein,
Mitochondrial) (WR OR = 0.79, 95%CI：0.69-0.91, FDR=0.09, PPH4 = 0.80)], TIMP4 [(Cd27
Antigen) (WR OR = 0.67, 95%CI：0.53-0.84, FDR=0.09, PPH4 = 0.83)] and MAP2K4
[(Metalloproteinase Inhibitor 4) (WR OR = 0.82, 95%CI：0.72-0.92, FDR=0.09，PPH4 = 0.80)].
(Table 1). Additionally, replication of these proteins can be obtained in the decode and UK Biobank
datasets (Table1).

3.2   Sensitivity analysis and Reverse causality detection for MN causal proteins

During the Phenoscanner process, no confounding factors were found. The preliminary analysis did
not detect any heterogeneity or horizontal pleiotropy in the analyzed proteins. In the reverse causal
analysis (with MN as the exposure and plasma proteins as the outcome), the aforementioned positive
proteins did not exhibit a causal relationship with membranous nephropathy. In addition, we resorted
to directional testing to evaluate causality. Furthermore, Steiger filtering provided additional

assurance regarding the presence of directional abnormalities. Steiger filtering consistently showed
the correct directionality, and the significance level was P < 0.05. In the HEIDI test, ABO, HRG, and
TIMP4 passed the test, while CD209 did not pass the test(Table 2). The remaining four proteins have
missing data.

3.3 Bayesian co-localization analysis

198 Through colocalization analysis，All significant proteins exhibit co-localization with moderate or

199 higher strength[strong Bayesian colocalization (PPH4 > 0.8) and Moderate-strength Bayesian
200 colocalization (0.5 < PPH4 < 0.8)]. This indicates that these significant plasma proteins share the
201 same variants with MN(Table 1).

3.4 SMR analysis for gene

203 After excluding the effects of heterogeneity and horizontal pleiotropy through the HEIDI test, we
204 identified a significant causal relationship between numerous genes and membranous nephropathy
205 based on gene prediction. Among them, VWF (ENSG00000110799) in the pqtl was validated
206 through SMR analysis using the eQTLgen database (Supplementary Table S1 and S2).

3.5 The correlation among causal proteins and current drug targets for MN

The PPI network unveiled an interrelationship involving three proteins (CD27) and an existing drug
target for MN (CD20 targeted by rituximab). Using STRING, the identified reliable protein
interaction axes include MS4A1-CD27-NCAM1, and MS4A1-NCAM1-CD27 (where NCAM1 has
been previously confirmed as a pathogenic antigen for MN) (Supplement Table S3). Therefore, we
should pay more attention to the relationship between MS4A1 and CD27. For unknown proteins,
CD27 is linked to the B lymphocyte antigen CD20 (MS4A1), which serves as the focus for
rituximab. Furthermore, STRING analysis unveiled physical interactions between the
aforementioned proteins and MS4A1, suggesting their close proximity without necessarily being in
direct contact. The phenotype scan revealed that the aforementioned correlated proteins remained
unaffected by other phenotypes, as all the phenotypes examined were unrelated to MN (Supplement
Table S4).

3.6 Mediation analysis

220 Our two-step analysis unveiled multiple factors that function as mediators in the causal pathway.
221 These include adult-onset asthma, beef intake, diabetes or endocrine disease, E-selectin levels, trunk
222 fat, type 1 diabetes with other specified/multiple/unspecified complications, and type 1 diabetes, all
223 of which have the potential to act as mediators in the associations between proteins and
224 diseases(Supplementary table S5).

4 Discussion

226 To our knowledge, this study represents the first attempt to integrate plasma proteomics data
227 with MR and Bayesian colocalization approaches using many databases to investigate the potential
228 involvement of specific proteins in MN. Furthermore, the relationship between genes and MN was
229 analyzed using SMR analysis. Based on genetic prediction, ABO, CD209, CD27, HRG, LRPPRC,
230 VWF, MAP2K4, and TIMP4 were found to have a causal relationship with MN. Through a series of

analyses, we ultimately identified ABO, HRG, and TIMP4 as high-priority potential drug targets for MN. Although CD27, CD209, VWF, LRPPRC, and MAP2K4 had a lower priority, they still hold suggestive significance. A one standard deviation (SD) change in the concentration of plasma proteins in the blood is associated with an odds ratio (OR) effect on MN. Our research in proteomics holds significance, as proteins, acting as effectors in numerous biological processes,(32) are widely regarded as drug targets, unlike previous studies that primarily focus on single phenotypes or even precise dual-disease MR, which are typically gene-centric analyses susceptible to the influence of gene-gene and gene-environment interactions. Taking advantage of the rapid advancement in high-throughput sequencing, we integrated genome-wide association studies (GWAS) with proteomics, enabling the integration of genetic and protein-level information. By utilizing MR and employing a series of validation methods, we have newly identified several promising proteins, thereby augmenting their potential as targets for therapeutic interventions. Hence, in order to identify innovative targets for drug intervention in MN, we utilized a comprehensive analysis to evaluate the causal involvement of proteins in MN. Causal relationships identified through MR may include reverse causality, horizontal pleiotropy, or genetic confounding induced by linkage disequilibrium (LD). Therefore, in this study, we adhered to the three fundamental principles of instrumental variable selection in Mendelian randomization analysis. We utilized IVs that exhibited strong correlations with plasma proteins. We excluded IVs that demonstrated linkage disequilibrium during the implementation of MR. The reverse Mendelian randomization analysis revealed that there is no reverse causal relationship between these proteins and MN. We utilized cis and trans pQTLs as IVs as they are implicated in the regulation of gene expression at both the transcriptional and translational levels. Cis-pQTLs refer to variants located proximal to the gene encoding the protein under study, while trans-pQTLs represent distal regulatory elements that influence proteins through often unknown mechanisms.(33,34) Trans-pQTLs offer valuable insights into molecular connections in human biology. Additionally, Bayesian colocalization was employed to eliminate bias introduced by LD.(35) Using a posterior probability threshold of 0.5, it was considered as moderate to high co-localization strength, and we identified 8 proteins that potentially share the same variants associated with MN. Nevertheless, these associations alone do not provide a complete explanation for the connection between the identified proteins and MN. Fortunately, Phenoscanner analysis unveiled associations of the IVs for these proteins with various phenotypes such as Duodenal ulcer, APTT, and thrombosis. These diverse phenotype associations are unrelated to MN, making it unlikely that the results are biased. Therefore, ABO, CD209, CD27, HRG, LRPPRC, VWF, MAP2K4, and TIMP4 may serve as potential drug targets for MN, with particular emphasis on ABO, HRG and TIMP4. We also conducted network and database searches for targeted drugs against CD27, such as MK-5890 (monoclonal antibody),(36) Varlilumab (monoclonal antibody),(37), and CDX-527 (bispecific antibody).(38) These drugs hold promise as novel targeted therapies for the treatment of MN.

ABO, Histo-blood group ABO system transferase is a critical protein involved in determining the ABO blood group system, which encompasses three carbohydrate antigens: A, B, and H. This protein facilitates the transfer of specific sugar molecules onto the surfaces of red blood cells, thereby determining an individual's blood type within the ABO system. This may suggest that blood type has an impact on the risk of developing MN.

CD209，CD209 antigen，The pathogen-recognition receptor is expressed on the surface of immature dendritic cells (DCs) and plays a crucial role in initiating the primary immune response. It is believed to mediate the endocytosis of pathogens, which are then degraded in lysosomal compartments. Subsequently, the receptor returns to the cell membrane surface, presenting pathogen-

derived antigens to resting T-cells through MHC class II proteins, thereby initiating the adaptive
immune response.

CD27 functions as a receptor for CD70/CD27L and may play a crucial role in the survival of
activated T-cells. The MR result suggests that for every one standard deviation increase in circulating
levels of CD27, there is a 0.784% decrease in the risk of MN. It is implicated in cellular apoptosis
through its interaction with SIVA1.(39) CD27 exhibits protein-protein interactions with CD20 and
NCAM1. While CD20-targeted therapy, rituximab, has become the mainstream treatment for MN.
The combination of PPI network analysis and MR revealed that therapeutic agents targeting CD27
have exhibited promising progress and evaluation in clinical trials, in contrast to the other identified
targets in our study. Currently, targeted drugs against CD27, such as MK-5890 (monoclonal
antibody), Varlilumab (monoclonal antibody), and CDX-527 (bispecific antibody), hold potential as
new targeted therapies for the treatment of MN. Based on our research findings, we hypothesize that
these antibodies may have an impact on MN, and therefore, we recommend future clinical studies to
further investigate this hypothesis.

HRG, also known as Histidine-Rich Glycoprotein. Plasma glycoprotein can bind to various
ligands, such as hemoglobin, acetylated hepari and plasminogen.

LRPPRC，The leucine-rich PPR motif-containing protein is involved in RNA metabolism in
both the nucleus and mitochondria. In the nucleus, it binds to poly(A) mRNAs and is associated with
mRNA maturation and export. In mitochondria, it binds to poly(A) mRNA and affects the translation
and stability of cytochrome c oxidase subunits.

VWF, also known as Von Willebrand Factor. It plays a vital role in hemostasis and serves as a
carrier for clotting factors. Upon blood vessel damage, a significant number of platelets adhere to
collagen fibers, forming a clot, where VWF acts as a mediator in hemostasis. The binding of VWF
factor to clotting factor VIII stabilizes and regulates its activity.

Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) is a protein kinase that
plays a crucial role in the MAP kinase signal transduction pathway, specifically in the stress-
activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. It directly activates
MAPK8/JNK1, MAPK9/JNK2, and MAPK10/JNK3, making it one of the few known kinases to do
so.

Metalloproteinase inhibitor 4 (TIMP-4) forms complexes with metalloproteinases, specifically
collagenases, and inactivates their activity by binding to the catalytic zinc cofactor.

In conclusion, we utilized proteomics and MR analysis to identify drug targets for MN. Unlike
previous studies that focused solely on the genetic level, our analysis incorporated both genetic and
protein levels. Considering the limited availability of targeted drugs for the treatment of MN, we
have successfully identified several potential therapeutic targets that require further investigation in
the future.

There are several limitations in our research. Firstly, the plasma protein data we utilized was
obtained from a combination of multiple proteomic studies, which may employ varying standards for
protein measurement. Nevertheless, we selected data that matched circulating protein data with
GWAS. Secondly, most proteins are associated with only one SNP, indicating either a lack of trans-
pQTL or cis-pQTL. Secondly, the data we employed in our experiments exclusively represented

European populations, necessitating further research to generalize the findings to other ethnicities. Thirdly, we did not observe any other proteins in the PPI network that are associated with CD20, except for CD27. This suggests that these proteins may be independent of CD20 and represent alternative potential targets. Additional research is warranted in this regard.

5 Data availability

Plasma pQTLs data was derived via public research. (14,20,21) MN data was retrieved from Kiryluk Lab.(22) We used R language version 4.3.0 for our analysis. In R language, we utilized the "coloc (https://github.com/chr1sallace/coloc.git)" and "TwoSampleMR (https://github.com/MRCIEU/TwoSampleMR.git)" , "MendelR" and "locuscompare" packages for our analysis.(40)

6 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

7 Author Contributions

The main efforts were jointly accomplished by Zhihang Su and Qijun Wan. Wen Liu, Zheng Yin, Di Wu, and Yuan Cheng participated in revising the manuscript.

8 Funding

Shenzhen Key Medical Discipline Construction Fund (SZXK009).

9 Acknowledgments

Sincere thanks to all participants who participated in the production of the public database.

10 References

1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2017 Jun 7;12(6):983–97.

2. Scolari F, Dallera N, Gesualdo L, Santoro D, Pani A, Santostefano M, et al. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ Open. 2019 Dec 4;9(12):e029232.

3. Caravaca-Fontán F, Fernández-Juárez GM, Floege J, Goumenos D, Kronbichler A, Turkmen K, et al. The management of membranous nephropathy-an update. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2022 May 25;37(6):1033–42.

4. Lin YC, Gau TS, Jiang ZH, Chen KY, Tsai YT, Lin KY, et al. Targeted therapy in glomerular diseases. J Formos Med Assoc Taiwan Yi Zhi. 2023 Jul 11;S0929-6646(23)00248-6.

5. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/33067605/

6.   Jhamb D, Magid-Slav M, Hurle MR, Agarwal P. Pathway analysis of GWAS loci identifies
novel drug targets and repurposing opportunities. Drug Discov Today. 2019 Jun;24(6):1232–6.

7.   King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be
approved? Revised estimates of the impact of genetic support for drug mechanisms on the
probability of drug approval. PLoS Genet. 2019 Dec;15(12):e1008489.

8.   Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug
repurposing. Nat Rev Genet. 2021 Oct;22(10):658–71.

9.   Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. Res Synth
Methods. 2019 Dec;10(4):486–96.

10.   Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide,
glossary, and checklist for clinicians. BMJ. 2018 Jul 12;362:k601.

11.   Henry A, Gordillo-Marañón M, Finan C, Schmidt AF, Ferreira JP, Karra R, et al. Therapeutic
Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.
Circulation. 2022 Apr 19;145(16):1205–17.

12.   Lin J, Zhou J, Xu Y. Potential drug targets for multiple sclerosis identified through Mendelian
randomization analysis. Brain J Neurol. 2023 Aug 1;146(8):3364–72.

13.   Chen J, Xu F, Ruan X, Sun J, Zhang Y, Zhang H, et al. Therapeutic targets for inflammatory
bowel disease: proteome-wide Mendelian randomization and colocalization analyses.
eBioMedicine [Internet]. 2023 Mar 1 [cited 2023 Aug 26];89. Available from:
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00059-2/fulltext

14.   Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide
Mendelian randomization mapping the influence of the plasma proteome on complex diseases.
Nat Genet. 2020 Oct;52(10):1122–31.

15.   Genomic atlas of the human plasma proteome - PubMed [Internet]. [cited 2023 Oct 4]. Available
from: https://pubmed.ncbi.nlm.nih.gov/29875488/

16.   Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, et al. Connecting genetic risk
to disease end points through the human blood plasma proteome. Nat Commun. 2017 Feb
27;8:14357.

17.   Yao C, Chen G, Song C, Keefe J, Mendelson M, Huan T, et al. Genome-wide mapping of plasma
protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat
Commun. 2018 Aug 15;9(1):3268.

18.   Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-regulatory
networks of human serum proteins link genetics to disease. Science. 2018 Aug
24;361(6404):769–73.

19.   Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Frånberg M, Sennblad B, et al.
Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet.
2017 Apr;13(4):e1006706.

20. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al.
Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021
Dec;53(12):1712–21.

21. Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic
associations with genetics and health in the UK Biobank. Nature. 2023 Oct;622(7982):329–38.

22. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al. The genetic architecture of membranous
nephropathy and its potential to improve non-invasive diagnosis. Nat Commun. 2020 Mar
30;11(1):1600.

23. Chen D, Zhang Y, Yidilisi A, Xu Y, Dong Q, Jiang J. Causal Associations Between Circulating
Adipokines and Cardiovascular Disease: A Mendelian Randomization Study. J Clin Endocrinol
Metab. 2022 May 17;107(6):e2572–80.

24. Huang D, Lin S, He J, Wang Q, Zhan Y. Association between COVID-19 and telomere length: A
bidirectional Mendelian randomization study. J Med Virol. 2022 Nov;94(11):5345–53.

25. Deng YT, Ou YN, Wu BS, Yang YX, Jiang Y, Huang YY, et al. Identifying causal genes for
depression via integration of the proteome and transcriptome from brain and blood. Mol
Psychiatry. 2022 Jun;27(6):2849–57.

26. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from
Mendelian randomization and colocalization: Review and comparison of approaches. Am J Hum
Genet. 2022 May 5;109(5):767–82.

27. Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et al.
Mendelian randomisation for mediation analysis: current methods and challenges for
implementation. Eur J Epidemiol. 2021 May;36(5):465–78.

28. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and
trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood
gene expression. Nat Genet. 2021 Sep;53(9):1300–10.

29. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major
update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074–82.

30. Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous
nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019
Jan;95(1119):23–31.

31. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING
database in 2023: protein-protein association networks and functional enrichment analyses for
any sequenced genome of interest. Nucleic Acids Res. 2023 Jan 6;51(D1):D638–46.

32. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk
and therapeutic targets - PubMed [Internet]. [cited 2023 Oct 4]. Available from:
https://pubmed.ncbi.nlm.nih.gov/37563310/

33. Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, et al. Plasma proteome analyses in
individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide
association studies. Nat Genet. 2022 May;54(5):593–602.

34. The genetic regulation of protein expression in cerebrospinal fluid - PubMed [Internet]. [cited
2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/36504281/

35. Mitochondrial related genome-wide Mendelian randomization identifies putatively causal genes
for multiple cancer types - PubMed [Internet]. [cited 2023 Oct 4]. Available from:
https://pubmed.ncbi.nlm.nih.gov/36634566/

36. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a
human CD27 activating antibody for cancer immunotherapy - PubMed [Internet]. [cited 2023 Oct
4]. Available from: https://pubmed.ncbi.nlm.nih.gov/36100308/

37. Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, et al. Safety and
Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients
With Advanced Solid Tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Jun 20;35(18):2028–
36.

38. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27
costimulation for cancer immunotherapy - PubMed [Internet]. [cited 2023 Oct 4]. Available
from: https://pubmed.ncbi.nlm.nih.gov/32451681/

39. Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, et al. CD27, a member of the tumor
necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc
Natl Acad Sci U S A. 1997 Jun 10;94(12):6346–51.

40. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations with gene
expression complicate GWAS follow-up. Nat Genet. 2019 May;51(5):768–9.

11   Figure legends

449 Figure 1: Study design

Exposure: Plasma proteins			Outcome: MN and IgAN
Discovery	Replication		Discovery
1699 plasma proteins (Zheng et al. 2020)	*Docode (Ferkingstad et al. 2021)* *UKBioBank (Sun et al. 2023)*		*MN (n=7,979)*

Proteome-wide Mendelian randomization	Sensitivity analysis	Additional analysis
Inverse variance weighted or Wald ratio	HEIDI test	**Colocalization analysis** **Reverse mendelian randomization** **stiger filtering**

Score

2 points	FDR < 0.05	PPH4 > 0.8	HEIDI test > 0.05	2 Replication
1 points	FDR < 0.10	PPH4 > 0.5		1 Replication

Threshold indicator

Drug targets

Proterin-protein Interaction Drug Bank

Mediation analysis

Two-step methods

Significant Gene analysis

SMR and HEIDI test